Search Results - noel+southall

11 Results

Sort By:

CD206 Small Molecule Modulators, Their Use and Methods for Preparation

Abstract: Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis – it is often asymptomatic in early stages – and a poor response to conventional...

Published: 4/8/2024 | Inventor(s): Udo Rudloff, Juan Marugan, Xin Hu, Raul Calvo, Noel Southall, Bolormaa Baljinnyam

Keywords(s): CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

The Use of Emetine for the Treatment of SARS-CoV-2 Infection

This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues...

Published: 7/25/2024 | Inventor(s): Mark Henderson, Juan Marugan, Andreas Dulcey Gracia, Xin Hu, Marc Ferrer-Alegre, Noel Southall

Keywords(s): Emetine, Infection, SARS-CoV-2, treatment, VLXXXX, WIXXXX, WKXXXX

Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Research Materials

Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction

This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...

Published: 7/25/2024 | Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan

Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials

Heterocyclic Compounds for the Treatment of Hepatitis C Virus

The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the...

Published: 7/25/2024 | Inventor(s): Zongyi Hu, Juan Marugan, Noel Southall, Xin Hu, Jingbo Xiao, Shanshan (Melissa) He, Marc Ferrer-Alegre, Wei Zheng, Kevin Frankowski, Frank Schoenen, Kelin Li, Tsanyang (Jake) Liang

Keywords(s): C, Class, compounds, DB4BXX, Development, Hepatitis, Novel, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

Novel Dopamine D2 Receptor Antagonists and Methods of Their Use

Investigators at the NIH have identified a series of novel, small molecule antagonists of the dopamine D2 receptor. Among the dopamine receptor (DAR) subtypes, D2 DAR is arguably one of the most validated drug targets in neurology and psychiatry. For instance, all receptor-based anti-Parkinsonian drugs work via stimulating the D2 DAR, whereas all FDA...

Published: 7/25/2024 | Inventor(s): Juan Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Noel Southall, R Benjamin Free, David Sibley

Keywords(s): Agents, ANTAGONISTS, ANTIPSYCHOTIC, D2, Dopamine, Human, NB2BXX, NB2XXX, Potential, RECEPTOR, SELECTIVE, VEXXXX, VNXXXX, WIXXXX, WKXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Psychiatry/Mental Health, TherapeuticArea > Neurology, Application > Research Materials, Application > Therapeutics

Novel Small Molecule Antimalarials for Elimination of Malaria Transmission

The transmission of malaria begins with injection of sporozoites into a human from the bite of a female anopheles mosquito, which initiates the malarial life cycle in humans. When a mosquito bites an infected human, the ingested male and female malaria gametocytes fuse to form a zygote that eventually becomes an oocyst. Each oocyst produces thousands...

Published: 7/25/2024 | Inventor(s): Wei Zheng, Seameen Dehdashti, Noel Southall, Wenwei Huang, Wei Sun, Takeshi Tanaka, John McKew

Keywords(s): compounds, DB2XXX, Gametocytocidal, Identification, Malaria, Novel, VOXXXX, WKXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, ResearchProducts > Research Equipment, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Consumer Products

Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis

The present invention is directed to novel small molecule agonists of the mammalian relaxin family receptor 1 (RXFP1), including human RXFP1. Activation of RXFP1 induces: 1) vasodilation due to up-regulation of the endothelin system; 2) extracellular matrix remodeling; 3) moderation of inflammation by reducing levels of inflammatory cytokines; and...

Published: 7/25/2024 | Inventor(s): Wei Zheng, Marc Ferrer-Alegre, Catherine Chen, Alexander Agoulnik, Noel Southall, Jingbo Xiao, Juan Marugan

Keywords(s): 1, IB1XXX, IB3XXX, IB5XXX, IB6XXX, IBXXXX, IXXXXX, MODULATORS, POTENT, RECEPTOR, Relaxin, RXFP1, SELECTIVE

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Cardiology, TherapeuticArea > Reproductive Health, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics

Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies

Gaucher disease is a rare lysosomal storage disease that is characterized by a loss of function of the glucocerebrosidase (GCase) enzyme, which results in a decreased ability to degrade its lipid substrate, glucocerebroside. The intracellular build up of this lipid causes a broad range of clinical manifestations, ranging from enlarged spleen/liver...

Published: 7/25/2024 | Inventor(s): Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Steven Rogers, Frank Schoenen, Juan Marugan

Keywords(s): CHAPERONES, Gaucher Disease, GLUCOCEREBROSIDASE, IBXXXX, NB1BXX, NBXXXX, NON-INHIBITORY, Parkinson's Disease, proteinopathy, UAXXXX, VEXXXX, WKXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Rare / Neglected Diseases

Methods of Treating Giardiasis Using FDA-Approved Compounds

This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia)...

Published: 7/25/2024 | Inventor(s): Catherine Chen, Juan Marugan, Noel Southall, Christopher Austin, Osnat Herzberg, Andrey Galkin, Wei Zheng

Keywords(s): compounds, DB2XXX, DBXXXX, DXXXXX, Giardiasis, NCTT, Novel, treatment

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Novel Small Molecule Inhibitors for the Treatment of Huntington’s Disease

This technology is a collection of small molecules screened for their ability to prevent or reduce the cytotoxic effects of the protein, Huntingtin. Huntington's disease is a neurodegenerative disorder due to a dominantly acting expansion of a CAG trinucleotide repeat in exon 1 of the Huntington (HTT) gene resulting in production of the altered (mutant)...

Published: 7/25/2024 | Inventor(s): Joshua McCoy, Samarjit Patnaik, Steven Titus, Wei Zheng, Noel Southall, Wenwei Huang, Juan Marugan

Keywords(s): ANALOGUES, Disease, HUNTINGTON'S, IB6XXX, IBXXXX, IXXXXX, NCTT, Novel, Thio-ether, treatment

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Reproductive Health, Application > Research Materials, Application > Diagnostics

1 2